

Phase 1 trial HMR code: 22-006

Submission date 13/07/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 25/07/2022	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 08/02/2023	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Scientific

Contact name

Dr Temitope Fadeke

Contact details

HMR
Cumberland Avenue
London
United Kingdom
NW10 7EW
+44 (0)20 8961 4130
rec@hmrlondon.com

Additional identifiers

Clinical Trials Information System (CTIS)

2022-001954-47

Integrated Research Application System (IRAS)

1005897

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Study information

Scientific Title

Phase 1 trial HMR code: 22-006

The full scientific title will be published within 30 months after the end of the trial

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 26/07/2022 London – Brent Research Ethics Committee (80 London Road, Skipton House, SE1 6LH, United Kingdom; +44 (0)207 1048137; brent.rec@hra.nhs.uk), ref: 22/LO/0430
2. Approved 26/07/2022 MHRA (10 South Colonnade, Canary Wharf, London E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 42719/0013/001-0001

Study design

Pharmacokinetic-interaction open-label crossover study

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

26/12/2022

Eligibility**Key inclusion criteria**

Healthy human volunteer

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

29/07/2022

Date of final enrolment

25/09/2022

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

HMR

Cumberland Avenue, Park Royal
London
United Kingdom
NW10 7EW

Sponsor information

Organisation

Heptares Therapeutics (United Kingdom)

ROR

<https://ror.org/051fk5x88>

Funder(s)

Funder type

Industry

Funder Name

Heptares Therapeutics (United Kingdom)

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available